Hypertension and Covid-19 vaccines: are there any differences between the different vaccines? A safety signal

被引：12

作者：

Bouhanick, Beatrice ^{[1
]}

Montastruc, Francois ^{[4
]}

Tessier, Samuel ^{[2
]}

Brusq, Clara ^{[3
]}

Bongard, Vanina ^{[3
]}

Senard, Jean-Michel ^{[2
]}

Montastruc, Jean-Louis ^{[4
]}

Herin, Fabrice ^{[5
]}

机构：

[1] Univ Paul Sabatier, INSERM, Ctr Hosp Univ, CERPOP,Serv Hypertens Arterielle & Therapeut, Toulouse, France

[2] Ctr Hosp Univ, CIC INSERM 1436, Fac Med Pharmacoepidemiol & Informat Medicament, Ctr Pharmacovigilance,Serv Pharmacol Med & Clin, Toulouse, France

[3] Univ Toulouse, Ctr Hosp, Unite Soutien Methodol Rech USMR, Toulouse, France

[4] Ctr Hosp Univ, INSERM, Fac Med, Inst Malad Metabol & Cardiovasc,Serv Pharmacol Me, F-1297 Toulouse, France

[5] Univ Paul Sabatier, INSERM, Hosp Univ Hop Purpan Purpan, Serv Sante Travail, Toulouse, France

来源：

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 2021年 / 77卷 / 12期

关键词：

D O I：

10.1007/s00228-021-03197-8

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：1937 / 1938

页数：2

共 6 条

[1] Case non-case studies: Principle, methods, bias and interpretation [J].

Faillie, Jean-Luc .

THERAPIE, 2019, 74 (02) :225-232

[2] Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases [J].

Khouri, Charles ;

Petit, Camille ;

Tod, Michel ;

Lepelley, Marion ;

Revol, Bruno ;

Roustit, Matthieu ;

Cracowski, Jean-Luc .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 2021, 134 :14-21

[3] Stage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination [J].

Meylan, Sylvain ;

Livio, Francoise ;

Foerster, Maryline ;

Genoud, Patrick James ;

Marguet, Francois ;

Wuerzner, Gregoire .

HYPERTENSION, 2021, 77 (06) :E56-E57

[4] Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database [J].

Montastruc, Jean-Louis ;

Sommet, Agnes ;

Bagheri, Haleh ;

Lapeyre-Mestre, Maryse .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (06) :905-908

[5] Pharmacovigilance - The next chapter [J].

Moore, Nicholas ;

Berdai, Driss ;

Blin, Patrick ;

Droz, Cecile .

THERAPIE, 2019, 74 (06) :557-567

[6] Is reporting rate a good predictor of risks associated with drugs? [J].

Pierfitte, C ;

Bégaud, B ;

Lagnaoui, R ;

Moore, ND .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (03) :329-331

← 1 →